Boxer Capital Management LLC Decreases Position in KalVista Pharmaceuticals, Inc. $KALV

Boxer Capital Management LLC lessened its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 78.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,400 shares of the specialty pharmaceutical company’s stock after selling 73,000 shares during the quarter. Boxer Capital Management LLC’s holdings in KalVista Pharmaceuticals were worth $248,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of KALV. BNP Paribas Financial Markets increased its position in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth $55,000. Wolverine Asset Management LLC purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter worth about $57,000. KLP Kapitalforvaltning AS purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter worth about $63,000. Finally, Virtus Investment Advisers LLC bought a new stake in KalVista Pharmaceuticals in the 2nd quarter valued at about $81,000.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. HC Wainwright boosted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC upped their price target on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $16.94 on Friday. The firm has a 50 day moving average of $15.76 and a 200-day moving average of $14.28. The firm has a market capitalization of $856.32 million, a P/E ratio of -4.29 and a beta of -0.35. KalVista Pharmaceuticals, Inc. has a 12 month low of $9.23 and a 12 month high of $19.00. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Insider Activity

In other news, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $83,361.78. Following the transaction, the insider owned 138,983 shares of the company’s stock, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $16.08, for a total value of $107,623.44. Following the completion of the sale, the chief executive officer owned 451,815 shares in the company, valued at $7,265,185.20. This trade represents a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 33,378 shares of company stock valued at $522,290. 4.30% of the stock is owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.